JNCE Stock Gains 25% After Updated Collaboration with Celgene
JNCE stock is moving up sharply following an update from Jounce Therapeutics (NASDAQ:JNCE) regarding its partnership with Celgene (NASDAQ:CELG). Investors Cheer the News Manufacturing of predictive biomarkers and immunotherapies is big business in the biotech ... [Read]